This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): clopidogrel bisulfate, SR25990C, Iscover
Description: Plavix (clopidogrel bisulfate) is in a class of medications called antiplatelet drugs. It works by helping to prevent harmful blood clots. Clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Clopidogrel acts by irreversibly modifying the platelet ADP receptor. Consequently, platelets exposed to clopidogrel are affected for the remainder of their lifespan.
Sanofi and Bristol-Myers Squibb
Sanofi and Bristol-Myers Squibb announced they have restructured their long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.The alliance currently operates under a framework consisting of two geographic territories, one covering certain European and Asian countries (other than Japan, which is not covered by the alliance), referred to as Territory A, and one covering the U.S., Puerto Rico, Canada, Australia and certain Latin American countries, referred to as Territory B.
Under the terms of the revised agreement, which will go into effect January 1, 2013, Bristol-Myers Squibb will return to Sanofi its rights to Plavix and Avapro/Avalide in all markets worldwide with the exception of Plavix in the U.S. and Puerto Rico, giving Sanofi sole control and freedom to operate commercially. In exchange, Bristol-Myers Squibb will receive royalty payments on Sanofis sales of branded and unbranded...See full deal structure in Biomedtracker
Partners: Bristol-Myers Squibb Company
Additional information available to subscribers only: